Structure Therapeutics
GPCR
119 hedge funds and large institutions have $1.86B invested in Structure Therapeutics in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 35 reducing their positions, and 26 closing their positions.
211% more call options, than puts
Call options by funds: $61.4M | Put options by funds: $19.8M
29% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 35
7% more capital invested
Capital invested by funds: $1.74B → $1.86B (+$127M)
0.62% more ownership
Funds ownership: 30.6% → 31.22% (+0.62%)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
2% less funds holding
Funds holding: 121 → 119 (-2)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$61.4M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$47.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$43.2M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$23.4M |
| 5 |
Janus Henderson Group
London,
|
+$22.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$95.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$39.9M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$21.6M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$14.8M |
GPCR Hedge Fund Activity: Q1 2024 in Review
119 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q1 2024, worth a combined $1.86B — up 7.3% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of GPCR and 25 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 45 added.
The largest buyer was Wellington Management Group, adding an estimated $61.4M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $95.1M sold.
- 119 institutional investors held Structure Therapeutics (GPCR) as of Q1 2024, down from 121 in Q4 2023.
- Funds reported $1.86B of Structure Therapeutics stock for Q1 2024, up 7.3% quarter-over-quarter.
- 25 funds opened new Structure Therapeutics positions in Q1 2024 and 26 closed out, a net change of -1 holder.
- The largest Structure Therapeutics buyer in Q1 2024 was Wellington Management Group, an estimated $61.4M added.
- The largest Structure Therapeutics seller in Q1 2024 was Avoro Capital Advisors, an estimated $95.1M sold.
Based on aggregated 13F filings for Q1 2024.